Pharvaris N.V. PHVS 深 沪
已收盘 09-26 16:00:00 美东时间
24.165
-0.415
-1.69%
华盛通- 最 高24.935
- 今 开24.51
- 成交量 8.15万股
- 最 低 23.86
- 昨 收 24.58
- 总市值 13.17亿
- 52周最高 26.33
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 11.51
- 委 比 99.93%
- 总股本 5449.31万
- 历史最高 42.86
- 量 比 0.26
- 振 幅 4.37%
- 历史最低 1.77
- 每 手 1
- 风险率 4.07%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pharvaris Secures Registration Rights Agreement with General Atlantic
Pharvaris ( ($PHVS) ) just unveiled an update. On September 2, 2025, Pharvaris ...
09-09 05:17
JMP Securities Maintains Market Outperform on Pharvaris, Lowers Price Target to $52
JMP Securities analyst Jonathan Wolleben maintains Pharvaris (NASDAQ:PHVS) with a Market Outperform and lowers the price target from $55 to $52.
08-13 22:21
Pharvaris Q2 EPS $(0.94) Misses $(0.87) Estimate
Pharvaris (NASDAQ:PHVS) reported quarterly losses of $(0.94) per share which missed the analyst consensus estimate of $(0.87) by 8.05 percent. This is a 59.32 percent decrease over losses of $(0.59) per share from the
08-13 04:41
Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update
Pharvaris reported progress on its late-stage clinical trials for deucrictibant, including RAPIDe-3 (on-demand treatment for HAE attacks, with topline results expected in 4Q2025), CHAPTER-3 (prophylaxis for HAE attacks, with results in 2H2026), and CREAATE (treatment for AAE-C1INH attacks, set to begin by year-end 2025). The company strengthened its financial position with a $201 million public offering, extending its cash runway into 1H2027. Pha...
08-12 20:05
Pharvaris prices $175M securities offering
Pharvaris (NASDAQ:PHVS) priced an underwritten offering of 8.25 million shares at $20 each and 500,000 pre-funded warrants at $19.99 each, raising around $175 million in gross proceeds. The company al...
07-23 13:20
Pharvaris shares are trading lower after the company announced a $150 million proposed public offering.
Pharvaris shares are trading lower after the company announced a $150 million p...
07-23 04:24
Pharvaris Announces Proposed Public Offering of Ordinary Shares
Pharvaris N.V., a biopharmaceutical company developing oral bradykinin B2 receptor antagonists for angioedema, plans to offer and sell $150 million of ordinary shares in an underwritten public offering, with an option for up to an additional $22.5 million. Proceeds will fund late-stage clinical programs, U.S. sales and marketing team hiring, commercialization, and general corporate purposes. Morgan Stanley, Leerink Partners, Cantor, Oppenheimer &...
07-22 20:05
美股周涨跌榜 | 加密货币概念股SharpLink周涨71%；CoreWeave周内暴跌23.8%，分析师喊话公司估值似乎过高
加密货币股SharpLink周涨71%；MP周涨超41%，公司与美国国防部签署战略合作协议；CoreWeave周内暴跌23.8%，分析师喊话公司估值似乎过高>>
07-12 10:03
Pharvaris Anticipates Reporting Topline Data From Rapide-3 In Q4 Of 2025; Expects To Submit NDA With FDA In H1 Of 2026
Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary
07-10 18:52
Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025
Pharvaris plans to submit the NDA for its deucrictibant IR capsule to the U.S. FDA in 1H2026 for the on-demand treatment of HAE attacks, following the expected topline data announcement from the RAPIDe-3 pivotal Phase 3 study in Q4 2025.
07-10 10:50
